A Agilent Technologies Inc.

Agilent Announces BioTek 406 FX Washer Dispenser for Technology-Driven Workflow Efficiency

(NYSE: A) today announced the release of the washer dispenser, a compact instrument that combines multifunctional reagent dispensing and plate-washing capabilities. The BioTek 406 FX offers expanded liquid handling features designed for integration into automated systems and standalone benchtop use.

Key features of the new BioTek 406 FX improve upon the benefits of the first-generation EL406 and include:

  • Secondary peristaltic and dual syringe pumps.
  • A touchscreen interface.
  • Enhanced flexibility for automated workflows across a broad range of applications, such as cell-based and magnetic bead-based assays. 

The additional reagent dispense pumps enable up to six different reagents to be dispensed using the pump technology best suited to each step of the workflow. Combining multiple assay workflow step capabilities in a single instrument is expected to be particularly beneficial for laboratories confronting space and budgetary constraints. The 406 FX plate carrier can be accessed from the right or left side, making it ideally suited for integration into robotic systems.

Caleb Foster, associate vice president of marketing for Agilent's Cell Analysis Division, discussed the impact of the release. "The launch of the 406 FX is an exciting step in the evolution of the Agilent BioTek liquid handling product line – one that incorporates years of customer feedback received from the EL406," he said. "This flexible platform replaces several instruments in one, with market-leading multifunctional capabilities.”

“It's a true workhorse instrument that can be used for cell-based assays, ELISA, and many other microplate-based workflows, and it brings the flexibility and reliability customers have come to expect from our products,” Foster added.

BioTek microplate washer dispensers are used widely throughout the life sciences industry. They are an integral part of a suite of automation-friendly Agilent solutions that aim to improve throughput and ease of use in complex end-to-end cell analysis workflows.

About Agilent Technologies

(NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, please subscribe to the Agilent . Follow Agilent on and .

EN
08/06/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Agilent Technologies, Inc.: Key facts and statistics - fiscal 2025

A summary company profile, detailing Agilent Technologies, Inc.’s business operations and financial highlights.

Agilent Technologies, Inc. - October 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Agilent Technologies, Inc.: Update to credit analysis

Our credit view of this issuer reflects its low financial leverage, against its high proportion of revenue from costly equipment sales, which has exposure to cyclical demand fluctuations

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Agilent Technologies, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 11 December 2025 in which we reassessed the appropriateness of the ratings in th...

Agilent Technologies Inc: 1 director

A director at Agilent Technologies Inc sold 2,600 shares at 149.812USD and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch